Test Price
2,800 AED✅ Home Collection Available
FLNB Gene Atelosteogenesis Type 1 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين FLNB لتشخيص تكون العظم الناقص من النوع الأول في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
🔬 Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing with full gene coverage and deletion/duplication analysis, validated against DHA/MOHAP standards.
🚑 Premium Logistics
Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy – 8 AM to 11 PM daily, all Emirates. يتم جمع العينات بسرية تامة وفقًا لأعلى معايير الخصوصية.
📋 Clinical Guidance
Telephonic Post-Test Clinical Guidance by DHA-licensed genetic counselors to interpret your FLNB variant report and its implications for your health and family.
💳 Insurance & Billing
Direct Billing Verification via WhatsApp at +971 54 548 8731. نتحقق من تغطية التأمين مباشرة عبر الواتس اب.
الملخص التنفيذي: اختبار جيني عالي الدقة لتشخيص تكون العظم الناقص من النوع الأول المرتبط بجين FLNB، معتمد من هيئة الصحة بدبي، يشمل استشارة وراثية وجمع عينات منزلي، والنتائج خلال 3-4 أسابيع.
Executive Summary: This definitive NGS test identifies pathogenic variants in the FLNB gene causing Atelosteogenesis Type 1 (AO1), a severe skeletal dysplasia. Governed by Federal Decree-Law No. 41 of 2024 (Art. 87), CDS Law 2026 for minors, and UAE PDPL, your genetic data is handled with utmost privacy and clinical rigor.
Test Overview & Clinical Utility
The FLNB Gene Atelosteogenesis Type 1 Genetic Test screens the entire coding region of the filamin B gene using next-generation sequencing for single nucleotide variants, small indels, and copy number variations implicated in lethal skeletal dysplasia AO1. This test is indicated for neonatal diagnosis, carrier screening, and familial variant tracking—crucial for definitive clinical management and genetic counseling. تحليل الجين كامل العمق يتيح تشخيصًا دقيقًا للحالات المعقدة.
| Test Parameter | Our Test (DHA-MOHAP Lab) | Closest Alternative (Conventional Sanger) |
|---|---|---|
| Precision | >99.9% analytical sensitivity, full exon coverage | ~98% for point mutations, limited CNV detection |
| Methodology | NGS with bioinformatic DHA-validated pipeline | Sanger sequencing of selected exons |
| Turnaround Time | 3–4 Weeks (expedited options) | 6–8 Weeks |
| Regulatory Compliance | ISO 9001:2015, MOHAP/DHA genetic testing license | Varies; often lacks UAE genetic law adherence |
Physician Insight & Patient Safety Protocol
“As a DHA-licensed specialist, I emphasize that a genetic diagnosis of Atelosteogenesis Type 1 carries profound clinical implications. The FLNB NGS test result must be correlated with radiographic findings and clinical phenotype; it is not a standalone predictor of severity. A negative result does not exclude other skeletal dysplasias, and any variant of uncertain significance warrants family studies. Your physician will integrate this data with your child’s complete health picture.”
— Dr. PRABHAKAR REDDY, DHA License: 61713011
⚠️ Medication Safety & Clinical Warnings
Do not discontinue prescribed medication without consulting your doctor.
- This test is not a substitute for emergency care. Seek immediate medical attention if your infant shows respiratory distress, severe limb deformity, or failure to thrive.
- Exclusion criteria: Inability to provide sufficient DNA sample (blood, FTA card, or extracted DNA); unavailability of genetic counseling session.
- ER Red Flags: Cyanosis, apnea, severe scoliosis, or joint dislocations demand urgent intervention independent of test status.
Patient FAQ & Clinical Guidance
What is the FLNB Gene Atelosteogenesis Type 1 NGS test, and how does it work?
This test uses next-generation sequencing to analyze the entire FLNB gene to detect DNA mutations causing Atelosteogenesis Type 1 (AO1), a severe skeletal disorder often lethal in the newborn period. The result guides reproductive planning and neonatal management.
يستخدم هذا الاختبار تقنية التسلسل الجيني المتقدم لتحليل كامل جين FLNB للكشف عن الطفرات المسببة لتكون العظم الناقص من النوع الأول، وهو اضطراب هيكلي حاد غالبًا ما يكون مميتًا في حديثي الولادة. تساعد النتيجة في التخطيط الإنجابي والعناية المركزة.
Why choose this over other genetic tests for skeletal dysplasia?
Our DHA-licensed lab offers ISO-certified, high-depth NGS with expert variant interpretation specific to Middle Eastern populations, unlike standard panels that may miss rare copy number changes. This targeted FLNB assay is the gold standard for suspected AO1.
مختبراتنا الحاصلة على اعتماد هيئة الصحة بدبي تقدم تحليلًا عالي الحساسية لتسلسل جين FLNB مع تفسير متخصص للطفرات النادرة، مما يجعله المعيار الذهبي لتشخيص تكون العظم الناقص من النوع الأول في المنطقة.
What is the turnaround time and sample collection process?
Results are delivered within 3–4 weeks after receipt of a blood sample, DNA extracted, or a single drop of blood on an FTA card, collected through our cold-chain home collection service. A genetic counseling session before sample submission is mandatory.
النتائج متاحة خلال 3-4 أسابيع بعد استلام العينة (دم كامل، حمض نووي مستخلص، أو نقطة دم على بطاقة FTA) عبر خدمة الجمع المنزلي المبردة. جلسة الاستشارة الوراثية إلزامية قبل تقديم العينة.
ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) • MOHAP Facility License: 9834453 • DHA Genetic Testing Regulations Complaint • Federal Decree-Law No. 41 of 2024, Art. 87 & CDS Law 2026 (Minors).
For appointments & insurance verification, WhatsApp: +971 54 548 8731 | © 2026 All rights reserved.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians